ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
momentum factor · long-only model fund

Foundry Healthcare 12-Month Momentum Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FMOHHYPOTHETICAL MODEL
Since ’99
+24%
Expense Ratio
0.45%
placeholder
Holdings
95
cap-weighted
Inception
Oct 2021
placeholder
Full Sharpe
0.18
Ann. Return (LS)
5.8%
Ann. Volatility
32.0%
Max Drawdown
-74.2%
Test Sharpe ’19–26
0.28
Test FF5 α (ann.)
9.6%
vs Fama-French 5
Test FF5 α t-stat
1.09
not significant
Monthly turnover
25%
of the long leg, per rebalance
Cumulative return (LS)
24%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.58
what this fund holds
Long leg ann. return
15.9%
buyable, long-only
Long-short Sharpe
0.18
requires shorting
Bottom bucket ann. return
10.1%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

95 of 95 · 100.0% of book
TickerCompanySectorMarket capWeight
1RVMD
REVOLUTION MEDICINES INCHealthcare$39.58B
10.80%
2CNC
CENTENE CORPHealthcare$32.81B
8.95%
3ROIV
ROIVANT SCIENCES LTDHealthcare$24.82B
6.77%
4GH
GUARDANT HEALTH INCHealthcare$20.67B
5.64%
5BTSG
BRIGHTSPRING HEALTH SERVICES INCHealthcare$13.71B
3.74%
6ARWR
ARROWHEAD PHARMACEUTICALS INCHealthcare$10.47B
2.86%
7APGE
APOGEE THERAPEUTICS INCHealthcare$10.10B
2.76%
8KYMR
KYMERA THERAPEUTICS INCHealthcare$9.52B
2.60%
9PRAX
PRAXIS PRECISION MEDICINES INCHealthcare$8.77B
2.39%
10SYRE
SPYRE THERAPEUTICS INCHealthcare$8.70B
2.37%
11IBRX
IMMUNITYBIO INCHealthcare$8.04B
2.19%
12PACS
PACS GROUP INCHealthcare$7.30B
1.99%
13LQDA
LIQUIDIA CORPHealthcare$7.11B
1.94%
14COGT
COGENT BIOSCIENCES INCHealthcare$6.68B
1.82%
15CGON
CG ONCOLOGY INCHealthcare$6.34B
1.73%
16ERAS
ERASCA INCHealthcare$5.96B
1.63%
17TWST
TWIST BIOSCIENCE CORPHealthcare$5.84B
1.59%
18DNTH
DIANTHUS THERAPEUTICS INCHealthcare$5.77B
1.58%
19ORKA
ORUKA THERAPEUTICS INCHealthcare$5.59B
1.53%
20TXG
10X GENOMICS INCHealthcare$5.55B
1.52%
21TVTX
TRAVERE THERAPEUTICS INCHealthcare$5.27B
1.44%
22DFTX
DEFINIUM THERAPEUTICS INCHealthcare$4.83B
1.32%
23VCYT
VERACYTE INCHealthcare$4.72B
1.29%
24LFST
LIFESTANCE HEALTH GROUP INCHealthcare$4.49B
1.23%
25CELC
CELCUITY INCHealthcare$4.31B
1.18%
26EWTX
EDGEWISE THERAPEUTICS INCHealthcare$4.28B
1.17%
27TNGX
TANGO THERAPEUTICS INCHealthcare$4.13B
1.13%
28RLAY
RELAY THERAPEUTICS INCHealthcare$3.81B
1.04%
29ALMS
ALUMIS INCHealthcare$3.65B
1.00%
30GPCR
STRUCTURE THERAPEUTICS INCHealthcare$3.45B
0.94%
31RCUS
ARCUS BIOSCIENCES INCHealthcare$3.44B
0.94%
32ELVN
ENLIVEN THERAPEUTICS INCHealthcare$3.24B
0.88%
33MBX
MBX BIOSCIENCES INCHealthcare$2.99B
0.82%
34TRVI
TREVI THERAPEUTICS INCHealthcare$2.71B
0.74%
35KOD
KODIAK SCIENCES INCHealthcare$2.67B
0.73%
36QURE
UNIQURE NVHealthcare$2.54B
0.69%
37SLS
SELLAS LIFE SCIENCES GROUP INCHealthcare$2.45B
0.67%
38NKTR
NEKTAR THERAPEUTICSHealthcare$2.31B
0.63%
39PVLA
PALVELLA THERAPEUTICS INCHealthcare$2.26B
0.62%
40SION
SIONNA THERAPEUTICS INCHealthcare$2.23B
0.61%
41AXGN
AXOGEN INCHealthcare$2.12B
0.58%
42GLUE
MONTE ROSA THERAPEUTICS INCHealthcare$2.07B
0.57%
43RAPP
RAPPORT THERAPEUTICS INCHealthcare$2.04B
0.56%
44DMRA
DAMORA THERAPEUTICS INCHealthcare$1.94B
0.53%
45TYRA
TYRA BIOSCIENCES INCHealthcare$1.91B
0.52%
46NEO
NEOGENOMICS INCHealthcare$1.90B
0.52%
47MRVI
MARAVAI LIFESCIENCES HOLDINGS INCHealthcare$1.87B
0.51%
48BCAX
BICARA THERAPEUTICS INCHealthcare$1.82B
0.50%
49STOK
STOKE THERAPEUTICS INCHealthcare$1.81B
0.49%
50BFLY
BUTTERFLY NETWORK INCHealthcare$1.73B
0.47%
51TSHA
TAYSHA GENE THERAPIES INCHealthcare$1.71B
0.47%
52ANAB
ANAPTYSBIO INCHealthcare$1.69B
0.46%
53FTRE
FORTREA HOLDINGS INCHealthcare$1.68B
0.46%
54CMPS
COMPASS PATHWAYS PLCHealthcare$1.67B
0.45%
55PSNL
PERSONALIS INCHealthcare$1.61B
0.44%
56INNV
INNOVAGE HOLDING CORPHealthcare$1.56B
0.43%
57SEPN
SEPTERNA INCHealthcare$1.51B
0.41%
58ABSI
ABSCI CORPHealthcare$1.29B
0.35%
59INBX
INHIBRX BIOSCIENCES INCHealthcare$1.28B
0.35%
60CRVS
CORVUS PHARMACEUTICALS INCHealthcare$1.25B
0.34%
61DRTS
ALPHA TAU MEDICAL LTDHealthcare$1.19B
0.33%
62ETON
ETON PHARMACEUTICALS INCHealthcare$1.16B
0.32%
63CAPR
CAPRICOR THERAPEUTICS INCHealthcare$1.13B
0.31%
64JBIO
JADE BIOSCIENCES INCHealthcare$1.03B
0.28%
65BIOA
BIOAGE LABS INCHealthcare$1.01B
0.28%
66ANRO
ALTO NEUROSCIENCE INCHealthcare$967M
0.26%
67AVR
ANTERIS TECHNOLOGIES GLOBAL CORPHealthcare$823M
0.22%
68ACRS
ACLARIS THERAPEUTICS INCHealthcare$793M
0.22%
69DSGN
DESIGN THERAPEUTICS INCHealthcare$785M
0.21%
70CLYM
CLIMB BIO INCHealthcare$727M
0.20%
71OMER
OMEROS CORPHealthcare$701M
0.19%
72TCMD
TACTILE SYSTEMS TECHNOLOGY INCHealthcare$648M
0.18%
73ACHV
ACHIEVE LIFE SCIENCES INCHealthcare$644M
0.18%
74STTK
SHATTUCK LABS INCHealthcare$577M
0.16%
75FDMT
4D MOLECULAR THERAPEUTICS INCHealthcare$575M
0.16%
76IMMX
IMMIX BIOPHARMA INCHealthcare$558M
0.15%
77RLMD
RELMADA THERAPEUTICS INCHealthcare$550M
0.15%
78CTNM
CONTINEUM THERAPEUTICS INCHealthcare$532M
0.15%
79ZURA
ZURA BIO LTDHealthcare$518M
0.14%
80NVCT
NUVECTIS PHARMA INCHealthcare$508M
0.14%
81KYTX
KYVERNA THERAPEUTICS INCHealthcare$453M
0.12%
82PBYI
PUMA BIOTECHNOLOGY INCHealthcare$434M
0.12%
83STRO
SUTRO BIOPHARMA INCHealthcare$391M
0.11%
84ZNTL
ZENTALIS PHARMACEUTICALS INCHealthcare$364M
0.10%
85QTTB
Q32 BIO INCHealthcare$255M
0.07%
86SRZN
SURROZEN INCHealthcare$255M
0.07%
87ARTV
ARTIVA BIOTHERAPEUTICS INCHealthcare$241M
0.07%
88KPTI
KARYOPHARM THERAPEUTICS INCHealthcare$216M
0.06%
89BDSX
BIODESIX INCHealthcare$204M
0.06%
90FOCL
FOCAL INCHealthcare$204M
0.06%
91VTVT
VTV THERAPEUTICS INCHealthcare$130M
0.04%
92SPRB
SPRUCE BIOSCIENCES INCHealthcare$120M
0.03%
93RLYB
RALLYBIO CORPHealthcare$87M
0.02%
94NRXS
NEURAXIS INCHealthcare$84M
0.02%
95EDSA
EDESA BIOTECH INCHealthcare$59M
0.02%

Full long-leg book as of July 2026 · cap-weighted · total market cap $366.51B. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

95 classified
Value
Blend
Growth
Large
Mid
Small
10%2
24%10
34%14
4%9
7%12
7%12
2%13
1%8
<1%4

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 86% toward Large, 64% toward Growth. +11% unclassified (11 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt86% → Large
SmallLarge
Value ↔ growth tilt64% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 95 names now. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
6
Failed
0
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

No verdict sits within 1.0pp of its limit.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 95 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
2.0 (95% CI 1.2-2.5)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
19.1%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
1.98x
within
parametric
1.74x
within
cornish fisher
2.03x
over · unreliable

The estimators agree, which is mild evidence the number isn’t an artefact of one method.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 1993
Entirely since publication
All 331 months of our record post-date the 1993 paper.
Sharpe 0.185.8% p.a.January 1999July 2026

There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
77%
20 of 26 3-year windows made money
Worst window
-0.46
Sharpe, January 2008 – December 2010
January 1999July 2026
Median Sharpe
0.17
Dispersion
0.32
Best window
0.71

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.43.8%-5.1%
3 yearsp.a.21.8%5.9%
5 yearsp.a.7.2%6.5%
10 yearsp.a.14.1%5.6%
Since inceptionp.a.13.0%0.8%
Calendar years
YearLong legLong-short
20267 mo22.4%11.7%
202517.9%1.8%
202432.7%29.8%
2023-9.5%-34.8%
2022-10.0%29.0%
202119.8%28.8%
202040.6%-8.6%
201929.8%-8.8%
2018-12.9%-0.6%
201737.4%23.6%
2016-20.2%19.8%
2015-18.6%-36.1%
201421.9%-14.9%
201372.7%27.2%
201222.2%-9.4%
201122.8%20.5%
201012.1%-12.0%
200925.8%-19.7%
2008-20.6%-3.2%
200716.8%37.1%
2006-9.6%-22.8%
200518.0%20.6%
200420.6%9.7%
200348.6%0.1%
2002-23.8%1.3%
2001-0.3%-7.6%
200021.7%-30.4%
199951.5%33.8%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FMOH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2021-10-14 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$366.51B

Methodology

The Foundry Healthcare 12-Month Momentum Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a 12-Month Momentum signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.